, Volume 40, Issue 2, pp 203–219 | Cite as

Effects of Drugs on Glucose Tolerance in Non-Insulin-Dependent Diabetics (Part II)

  • Sharon O’Byrne
  • John Feely
Review Article


Insulin Secretion Glucose Tolerance Captopril British Medical Journal Pentamidine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abadie E, Passa PH. Diabetogenic effects of nifedipine. Correspondence. British Medical Journal 289: 438, 1984Google Scholar
  2. Adams PW, Godsland I, Melrose J, et al. The influence of oral contraceptive formulation on carbohydrate and lipid metabolism. Journal of Pharmacotherapy 3: 54, 1980PubMedGoogle Scholar
  3. Adams PW, Oakley NW. Oral contraceptives and carbohydrate metabolism. Clinics in Endocrinology and Metabolism 1: 697–720, 1972PubMedGoogle Scholar
  4. Adnitt PI. Hypoglycaemic action of monoamineoxidase inhibitors (MAOIs). Diabetes 17: 628–633, 1968PubMedGoogle Scholar
  5. Amery A, Berthaux P, Bulpitt C, Deruyttere M, De Schaepdryver A, et al. Glucose intolerance during diuretic therapy: results of trial by the European Working Party on Hypertension in the Elderly. Lancet 1: 681–683, 1978PubMedGoogle Scholar
  6. Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients: a second report from the European Working Party on high blood pressure in the elderly (EWPHE). Postgraduate Medical Journal 62: 919–924, 1986PubMedGoogle Scholar
  7. Amery A, Brixko P, Clement D, De Schaepdryver A, Fagaro R, et al. Mortality and morbidity results from the European Working Party on high blood pressure in the elderly trial. Lancet 1: 1349–1354, 1985PubMedGoogle Scholar
  8. Ames RP, Hill P. Antihypertensive therapy and the risk of coronary heart disease. Journal of Cardiovascular Pharmacology 4 (Suppl. 2): 206–212, 1982Google Scholar
  9. Andersson DEH, Röjdmark S. Improvement of glucose tolerance by verapamil in patients with non-insulin dependent diabetes mellitus. Acta Medica Scandinavica 210: 27–33, 1981PubMedGoogle Scholar
  10. Arneson GA. Phenothiazine derivatives and glucose metabolism. Journal of Neuropsychiatry 5: 181–185, 1964PubMedGoogle Scholar
  11. Ashmore J. The effect of glucocorticoids on insulin action. Diabetes 13: 349–354, 1964PubMedGoogle Scholar
  12. Awoke S, Voyles NR, Bhathena SJ, Tanenberg RJ, Recant L. Alterations of plasma opioid activity in human diabetes. Life Sciences 34: 1999–2006, 1984PubMedGoogle Scholar
  13. Baldwin HS, Dworetsky M, Isaacs NJ. Evaluation of the steroid treatment of asthma since 1950. Journal of Allergy 32: 109–118, 1961PubMedGoogle Scholar
  14. Barnett D, Craig JG, Robinson DS, Rogers MP. Effect of clofibrate on glucose tolerance in maturity onset diabetes. British Journal of Clinical Pharmacology 4: 455–458, 1977PubMedGoogle Scholar
  15. Beable A, Ghurye RS, Micallef-Eynaud P, Baksi AK. Nifedipine and bendrofluazide in the treatment of hypertension in noninsulin-dependent diabetics. Practical Diabetes 6: 233–237, 1989Google Scholar
  16. Beck P, Schalch DS, Parker ML, Kipnis DM, Daughaday WH. Correlative studies of growth hormone and insulin plasma concentrations with metabolic abnormalities in acromegaly. Journal of Laboratory Clinical Medicine 66: 366–379, 1965Google Scholar
  17. Belehu A, Naafs B. Diabetes mellitus associated with pentamidine mesylate. Correspondence. Lancet 2: 1463–1464, 1982Google Scholar
  18. Belehu A, Naafs B, Touw-Langendijk E. Failure of metronidazole treatment in Ethiopian mucocutaneous Leishmaniasis. British Journal of Dermatology 99: 421–422, 1978PubMedGoogle Scholar
  19. Benfield GF, Hunter KR. Oxprenolol methyldopa and lipids in diabetes mellitus. British Journal of Clinical Pharmacology 13: 219–222, 1982PubMedGoogle Scholar
  20. Bengtsson C, Blohmé G, Lapidus L, et al. Do antihypertensive drugs precipitate diabetes? British Medical Journal 289: 1495–1497, 1984PubMedGoogle Scholar
  21. Bengtsson C, Blohmé G, Lapidus L, Lundren H. Diabetes in hypertensive women: an effect of antihypertensive drugs on the hypertensive state perhaps. Diabetic Medicine 5: 261–264, 1988PubMedGoogle Scholar
  22. Berglund G, Andersson O. Beta-blockers or diuretics in hypertension? A six-year follow-up of blood pressure and metabolic side effects. Lancet 1: 744–747, 1981PubMedGoogle Scholar
  23. Berglund G, Larsson B, Andersson O, Larsson O, Svärdsudd K, et al. Body composition and glucose metabolism in hypertensive middle-aged males. Acta Medica Scandinavica 200: 163–169, 1976PubMedGoogle Scholar
  24. Bhatnagar SK, Amin MMA, Al-Yusuf AR. Diabetogenic effects of nifedipine. British Medical Journal 289: 19, 1984PubMedGoogle Scholar
  25. Bilo HJH, Westerman RF, Nicolaas-Merkus AM, Donker AJM. Effects of enalapril with and without hydrochlorothiazide in hypertensive patients with non-insulin-dependent diabetes mellitus. Diabetes Research 9: 21–25, 1988PubMedGoogle Scholar
  26. Bjorck S, Nyberg G, Mulec H, Granerus G, Herlitz H, et al. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. British Medical Journal 293: 471–474, 1986PubMedGoogle Scholar
  27. Blane GF. Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. American Journal of Medicine 83: 26–36, 1987PubMedGoogle Scholar
  28. Blazar BR, Whitley CB, Kitabchi AE, Tsai MY, Santiago J, et al. In vivo chloroquine induced inhibition of insulin degradation in a diabetic patient with severe insulin resistance. Diabetes 33: 1133–1137, 1984PubMedGoogle Scholar
  29. Bloomgarden ZT, Ginsberg-Fellner F, Fayfield EJ, Bookman J, Brown WV. Elevated haemoglobin A1C and low density lipoprotein cholesterol levels in thiazide treated diabetic patients. American Journal of Medicine 77: 823–827, 1984PubMedGoogle Scholar
  30. Bouchard P, Sai P, Reach G, Caubarrère I, Ganeval D. Diabetes mellitus following pentamidine-induced hypoglycaemia in humans. Diabetes 31: 40–45, 1982PubMedGoogle Scholar
  31. Bougneres PF, Carel JC, Castano L, Boitard C, Gardin JP, et al. Factors associated with early remission of Type I diabetes in children treated with cyclosporine. New England Journal of Medicine 318: 663–670, 1988PubMedGoogle Scholar
  32. Bratusch-Marrain PR, Vierhapper H, Komjati M, Waldhausl WK. Acetyl-salicylic acid impairs insulin-mediated glucose utilization and reduces insulin clearance in healthy and non-insulin dependent diabetic man. Diabetologia 28: 671–676, 1985PubMedGoogle Scholar
  33. Breckenridge A, Welborn TA, Dollery CT, Fraser F. Glucose tolerance in hypertensive patients on long-term diuretic therapy. Lancet 1: 61–64, 1967PubMedGoogle Scholar
  34. Broadstone VL, Pfeifer MA, Bajaj V, Stagner JI, Samols E. α-Adrenergic blockade improves glucose-potentiated insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes 36: 932–937, 1987PubMedGoogle Scholar
  35. Bruni JF, Watkins WB, Yen SSC. Beta-endorphin in the human pancreas. Journal of Clinical Endocrinology and Metabolism 49: 649–651, 1979PubMedGoogle Scholar
  36. Bryceson ADM. Pentamidine induced diabetes mellitus. East African Medical Journal 45: 110–117, 1968PubMedGoogle Scholar
  37. Buchler D, Warren JC. Effects of estrogen on glucose tolerance. American Journal of Obstetrics and Gynaecology 95: 479–483, 1966Google Scholar
  38. Butler WJ, Ostrander Jr LD, Carman WJ, Lamphiear DE. Diabetes mellitus in Tecumseh, Michigan: prevalence, incidence and associated conditions. American Journal of Epidemiology 116: 971–980, 1982PubMedGoogle Scholar
  39. Byam N, Patrick AL. Efficacy and safety of medium term indapamide treatment in hypertensive diabetic patients. West Indian Medical Journal 34: 261–264, 1985PubMedGoogle Scholar
  40. Cantarovich D, Murat A, Hourmant M, Bardet S, Soulillou JP. Is cyclosporine toxic for human pancreas? Transplantation Proceedings XX (Suppl. 3): 449–452, 1988Google Scholar
  41. Caprio S, Ray TK, Boden G, Reichard Jr GA, Shuman CR, et al. Improvement of metabolic control in diabetic patients during mebendazole administration: preliminary studies. Diabetologia 27: 52–55, 1984PubMedGoogle Scholar
  42. Caro JF, Muller G, Glennon JA. Insulin processing by the liver. Journal of Biological Chemistry 257: 8459–8466, 1982PubMedGoogle Scholar
  43. Caruso M, Orszulak TA, Miles JM. Lactic acidosis and insulin resistance associated with epinephrine in a patient with noninsulin-dependent diabetes mellitus. Archives of Internal Medicine 147: 1422–1424, 1987PubMedGoogle Scholar
  44. Castrignano R, D’Angelo A, Pati T, Al Awady M, Tronca R, et al. A single-blind study of doxazosin in the treatment of mildto-moderate essential hypertensive patients with concomitant non-insulin-dependent diabetes mellitus. American Heart Journal 116: 1778–1784, 1988PubMedGoogle Scholar
  45. Ceriello A, Giugliano D, Dello Russo P, Sgambato S, D’Onofrio F. Increased glycosylated haemoglobin A1 in opiate addicts: evidence for hyperglycemic effect of morphine. Correspondence. Diabetologia 22: 379, 1982Google Scholar
  46. Chaffman M, Heel RC, Brogden RN, Speight TM, Avery GS. Indapamide: a review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 28: 189–235, 1984PubMedGoogle Scholar
  47. Change KJ, Cuatrecasas P. Heterogeneity and properties of opiate receptors. Federation Proceedings 40: 2729–2734, 1981Google Scholar
  48. Chapman MG. Salbutamol induced acidosis in pregnant diabetics. British Medical Journal 1: 639–640, 1977PubMedGoogle Scholar
  49. Charles S, Keterslegers JM, Buyschaert M, Lambert AE. Hyperglycaemic effect of nifedipine. British Medical Journal 283: 19–20, 1981PubMedGoogle Scholar
  50. Clissold SP, Brogden RN. Piretanide: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 29: 489–530, 1985PubMedGoogle Scholar
  51. Collins WCJ, Cullen MJ, Feely J. Calcium channel blocker drugs and diabetic control. Clinical Pharmacology and Therapeutics 42: 420–423, 1987PubMedGoogle Scholar
  52. Colwell JA. Inhibition of insulin secretion by catecholamines in pheochromocytoma. Annals of Internal Medicine 71: 251–256, 1969PubMedGoogle Scholar
  53. Conn J, Fajans S. Influence of adrenal cortical steroids on carbohydrate metabolism. Metabolism 5: 114–127, 1956PubMedGoogle Scholar
  54. Connacher AA, Eidenbani AH, Isles TE, Stevenson IH. Disposition and hypoglycaemic action of glipizide in diabetic patients given a single dose of nifedipine. European Journal of Clinical Pharmacology 33: 81–83, 1987PubMedGoogle Scholar
  55. Connor H, Marks V. Alcohol and diabetes. Diabetic Medicine 2: 413–416, 1985PubMedGoogle Scholar
  56. Conrad KA, Fagan TC, Lee SM, Simons JA. Effect of tripamide on glucose tolerance in patients with hypertension. Clinical Pharmacology and Therapeutics 40: 476–479, 1986PubMedGoogle Scholar
  57. Crane MG, Harris JJ. Effect of spironolactone in hypertensive patients. American Journal of Medical Science 260: 311–330, 1970Google Scholar
  58. Crosley Jr JP, Ronquillo LM, Strickland WH, Alexander F. Triamterene, a new natriuretic agent: preliminary observations in man. Annals of Internal Medicine 56: 241–251, 1962PubMedGoogle Scholar
  59. Cruz-Vidal M, Costas Jr R, Garcia-Palmieri MR, Sorlie PD, Hertzmark E. Factors related to diabetes mellitus in Puerto Rican men. Diabetes 28: 300–307, 1979PubMedGoogle Scholar
  60. Cudworth AG, Cunningham JL. The effect of diphenylhydantoin on insulin response. Clinical Science and Molecular Medicine 46: 131–136, 1974PubMedGoogle Scholar
  61. Dargie HJ, Dollery CT. Adverse reactions to diuretic drugs. In Dukes MNG (Ed.) Meyler’s side effects of drugs, Vol. 8, pp. 491, Excerpta Medica, Amsterdam, 1975Google Scholar
  62. Davidson MB. The effect of aging on carbohydrate metabolism: a review of the English literature and a practical approach to the diagnosis of diabetes mellitus in the elderly. Metabolism 28(6): 688–705, 1979PubMedGoogle Scholar
  63. De Fronzo RA, Ferrannini E, Koivisto V. New concepts in the pathogenesis and treatment of non-insulin-dependent diabetes mellitus. American Journal of Medicine 74 (Suppl. 1): 52–80, 1983Google Scholar
  64. Dodson PM, Beevers M, Hallworth R, Webberley MJ, Fletcher RF, et al. Sodium restriction and blood pressure in hypertensive Type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. British Medical Journal 298: 227–230, 1989PubMedGoogle Scholar
  65. Dollery CT, Pentecost BL, Samaan NA. Drug-induced diabetes. Lancet 2: 735–737, 1962PubMedGoogle Scholar
  66. Dominguez JR, de la Calle H, Hurtado A, Robles RG, SanchoRof J. Effect of converting enzyme inhibition in hypertensive patients with non-insulin-dependent diabetes mellitus. Postgraduate Medical Journal 62 (Suppl. 1): 66–68, 1986PubMedGoogle Scholar
  67. Donnelly T, Harrower ADB. Effect of nifedipine on glucose tolerance and insulin secretion in diabetic and non-diabetic patients. Current Medical Research Opinion 6: 690–693, 1980Google Scholar
  68. Dornhorst A, Ouyang A. Effect of alcohol on glucose tolerance. Lancet 2: 957–959, 1971PubMedGoogle Scholar
  69. Dornhorst A, Powell SH, Pensky J. Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in Type II diabetes without alteration of insulin secretion. Lancet 1: 123–126, 1985PubMedGoogle Scholar
  70. Dukes MNG (Ed.). Meyler’s side effects of drugs, 10th ed., Elsevier, Amsterdam, New York, 1984Google Scholar
  71. Dunn JP, Ipsen J, Elsom KO, Ohtani M. Risk factors in coronary artery disease, hypertension and diabetes. American Journal of Medical Science 259: 309–322, 1970Google Scholar
  72. Epstein FH, Ostrander LD, Johnson BC, Payne MW, Hayner NS, et al. Epidemiological studies of cardiovascular disease in a total community: Tecumseh, Michigan. Annals of Internal Medicine 62: 1170–1187, 1965PubMedGoogle Scholar
  73. Exton JH, Mallette LE, Jefferson LS, Wong EHA, Friedmann N, et al. The hormonal control of hepatic gluconeogenesis. Recent Progress in Hormone Research 26: 411–461, 1970PubMedGoogle Scholar
  74. Fariss B, Lutcher CL. Diphenylhydantoin-induced hyperglycaemia and impaired insulin release. Diabetes 20: 177–181, 1971Google Scholar
  75. Feldberg WS, Smyth DG. C-fragment of lipotropin: an endogenous potent analgesic peptide. British Journal of Pharmacology 60: 445–453, 1977PubMedGoogle Scholar
  76. Feldman JM, Boyd AE, Lebovitz HE. Structural determinants of catecholamine action on in vitro insulin release. Journal of Pharmacology and Experimental Therapeutics 176: 611–621, 1971PubMedGoogle Scholar
  77. Felig PL. Glucagon: physiologic and diabetogenic role. New England Journal of Medicine 283: 149–150, 1970PubMedGoogle Scholar
  78. Fenderson RW, Deutsch S, Menachemi E, Chin B, Samuel P. Effect of gemfibrozil on serum lipids in man. Angiology 33: 581–593, 1982PubMedGoogle Scholar
  79. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, et al. Insulin resistance in essential hypertension. New England Journal of Medicine 317: 350–357, 1987PubMedGoogle Scholar
  80. Ferrari C, Frezzati S, Romussi M, Bertazzoni A, Testori GP, et al. Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridaemia. Metabolism 26: 129–139, 1977PubMedGoogle Scholar
  81. Fernere M, Lachkar H, Rochard J-L, Bringer J, Orsetti A, et al. Captopril and insulin sensitivity. Correspondence. Annals of Internal Medicine 102: 134–135, 1985Google Scholar
  82. Field JB. Extraction of insulin by liver. Annual Review of Medicine 24: 309–314, 1973PubMedGoogle Scholar
  83. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. New England Journal of Medicine 317: 1237–1245, 1987PubMedGoogle Scholar
  84. Friedenberg R, Metz R, Mako M, Surmaczynska B. Differential plasma insulin response to glucose and glucagon stimulation following ethanol priming. Diabetes 20: 397–403, 1971PubMedGoogle Scholar
  85. Fulcher GR, Jones IR, Alberti KGMM. Improvement in glucose tolerance by reduction of lipid concentrations in non-insulindependent diabetes mellitus. Diabetes News IX: 4–6, 1988Google Scholar
  86. Fuller JH, McCartney P, Jarrett RJ, Keen H, Rose G, et al. Hyperglycaemia and coronary heart disease: the Whitehall Study. Journal of Chronic Diseases 32: 721–728, 1979PubMedGoogle Scholar
  87. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary heart disease risk and impaired glucose tolerance: the Whitehall Study. Lancet 2: 1373–1376, 1980Google Scholar
  88. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall Study. British Medical Journal 287: 867–870, 1983PubMedGoogle Scholar
  89. Garg A, Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. New England Journal of Medicine 318: 81–86, 1988PubMedGoogle Scholar
  90. Garrett BN, Raskin P, Kaplan NM. Metoprolol in diabetes mellitus: effect on glucose homeostasis. Clinical Science 59(Suppl. 6): 469–472, 1980Google Scholar
  91. Gill JS, Al-Hussary N, Atkins TW, Taylor KG, Beevers DG. Possible role for insulin receptors in the mechanism of thiazide induced glucose tolerance. Journal of Hypertension 2 (Suppl. 3): 573–576, 1984Google Scholar
  92. Giugliano D, Ceriello A, Di Pinto P, Saccomanno F, Gentile S, et al. Impaired insulin secretion in human diabetes mellitus: the effect of naloxone-induced opiate receptor blockade. Diabetes 31: 367–370, 1982PubMedGoogle Scholar
  93. Giugliano D, Quatraro A, Ceriello A, D’Onofrio F. Endogenous opiates, heroin addiction, and noninsulin-dependent diabetes. Lancet 2: 769–770, 1985PubMedGoogle Scholar
  94. Giugliano D, Torella R, Cacciapuoti F, Gentile S, Verza M, et al. Impairment of insulin secretion in man by nifedipine. European Journal of Clinical Pharmacology 18: 395–398, 1980PubMedGoogle Scholar
  95. Giugliano D, Torella R, Sgambato S, D’Onofrio F. Acetylsalicylic acid restores acute insulin response reduced by frusemide in man. Diabetes 28: 841–845, 1979PubMedGoogle Scholar
  96. Goa KL, Campoli-Richards DM. Pentamidine isethionate: a review of its antiprotozoal activity, pharmacokinetic properties and therapeutic use in Pneumocystis carinii pneumonia. Drugs 33: 242–258, 1987PubMedGoogle Scholar
  97. Goldberg EM, Sanbar SS. Hyperglycaemic, non-ketotic coma following administration of Dilantin (diphenylhydantoin). Diabetes 18: 101–106, 1969PubMedGoogle Scholar
  98. Goldner MG, Zanowitz H, Akgour S. Hyperglycaemia and glycosuria due to thiazide derivatives administered in diabetes mellitus. New England Journal of Medicine 262: 403–405, 1960PubMedGoogle Scholar
  99. Greenblatt DJ, Duhme DW, Allen MD, Koch-Weser J. Clinical toxicity of frusemide in hospitalised patients: a report from the Boston Collaborative Drug Surveillance Program. American Heart Journal 94: 6–13, 1977PubMedGoogle Scholar
  100. Greenwood RH, Luzio SD, Gibby O, Mahler RF, Hales CN. The pharmacological modification of insulin secretion. In Waldhausl WK (Ed.) Proceedings of the 10th Congress of the IDF, Vienna, Austria, International Congress Series No. 500, pp. 566–570, Excerpta Medica, Amsterdam, 1979Google Scholar
  101. Grodsky GM, Bennett LL. Cation reqúirements for insulin secretion in the isolated perfused pancreas. Diabetes 15: 910–912, 1966PubMedGoogle Scholar
  102. Gündo~gdu AS, Brown PM, Juul S, Sachs L, Sönksen PH. Comparison of hormonal and metabolic effects of salbutamol infusion in normal subjects and insulin-requiring diabetics. Lancet 2: 1317–1321, 1979Google Scholar
  103. Guthrie GP. Low dose oral and transdermal therapy of hypertension. In Weber MA et al. (Eds) Diabetes and hypertension, pp. 39–43, Springer-Verlag, New York, 1985Google Scholar
  104. Halter JB, Graf RJ, Porte Jr D. Potentiation of insulin secretory responses by plasma glucose levels in man: evidence that hyperglycemia in diabetes compensates for impaired glucose potentiation. Journal of Clinical Endocrinology and Metabolism 48: 946–954, 1979PubMedGoogle Scholar
  105. Hamman RF, Bennett PH, Miller M. Incidence of diabetes among the Pima Indians. In Levine R & Lust R (Eds) Advances in metabolic disorders, Vol. 9, pp. 49–63, Academic Press, New York, 1978Google Scholar
  106. Harrower ADB, McFarlane G. Antihypertensive therapy in diabetic patients: the use of indapamide. American Journal of Medicine 84 (Suppl. 1B): 89–91, 1988PubMedGoogle Scholar
  107. Harrower ADB, McFarlane G, Donnelly T, Gray CE. Blood pressure and diabetic control: results of indapamide treatment. Practitioner 228: 602–603, 1984PubMedGoogle Scholar
  108. Hauger-Klevene JH, Scornavacchi JC. The improvements of glucose tolerance in hypertensive diabetic patients treated with guanfacine one year. European Journal of Clinical Pharmacology 29: 391–393, 1985PubMedGoogle Scholar
  109. Helderman JH, Elahi D, Andersen DK, Raizes GS, Tobin JD, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 32: 106–111, 1983PubMedGoogle Scholar
  110. Helgeland A, Hagelund CH, Strammen R, Tretli S. Enalapril, atenolol and hydrochlorothiazide in mild to moderate hypertension. Lancet 1: 872–875, 1986PubMedGoogle Scholar
  111. Hellman B. The significance of calcium for glucose stimulation of insulin release. Endocrinology 97: 392–398, 1975PubMedGoogle Scholar
  112. Heninger GR, Mueller PS. Carbohydrate metabolism in mania. Archives of General Psychiatry 23: 310–319, 1970PubMedGoogle Scholar
  113. Henquin JC, Charles S, Henquin M, Mathot F, Tamagawa T. Diazoxide and D600 inhibition of insulin release. Diabetes 31: 776–783, 1982PubMedGoogle Scholar
  114. Henwood JM, Heel RC. Lovastatin: a preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs 36: 429–454, 1988PubMedGoogle Scholar
  115. Henwood JM, Todd PA. Ibopamine: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 36: 11–31, 1988PubMedGoogle Scholar
  116. Herriott SC, Percy-Robb IW, Strong JA, Thomson CG. The effect of Atromid on serum cholesterol and glucose tolerance in diabetes mellitus. Journal of Atherosclerotic Research 3: 679–688, 1963Google Scholar
  117. Hicks BH, Ward JD, Jarrett RJ, Keen H, Wise P. A controlled study of clopamide, clorexolone and hydrochlorothiazide in diabetics. Metabolism 22: 101–109, 1973PubMedGoogle Scholar
  118. Hiles BW. Hyperglycemia and glycosuria following chlorpromazine therapy. Correspondence. Journal of the American Medical Association 162: 1651, 1956Google Scholar
  119. Hopper AH, Tindall H, Davies JA. Effect of aspirin on glucose tolerance and insulin levels in patients with Type 2 diabetes mellitus. Correspondence. Thrombosis and Haemostasis 54: 895, 1985Google Scholar
  120. Hosker JP, Burnett MA, Davies EG, Matthews DR, Rudenski A, et al. Loss of normal sigmoid dose-response curve to glucose in non-insulin dependent diabetes. Abstract no. 232. Diabetologia 27: 289A, 1984Google Scholar
  121. Houston MC. Clonidine hydrochloride. Southern Medical Journal 75: 713–721, 1982PubMedGoogle Scholar
  122. Hutchinson JG. The hypotensive action of ethacrynic acid. Vascular Diseases 5: 104–117, 1968Google Scholar
  123. Illingworth DR. Lipid-lowering drugs. Drugs 33: 259–279, 1987PubMedGoogle Scholar
  124. Janka HU, Ziegler AG, Disselhoff G, Mehnert H. Influence of bisoprolol on blood glucose, glucosuria and haemoglobin A1 in noninsulin-dependent diabetics. Journal of Cardiovascular Pharmacology 8 (Suppl. 11): 96–99, 1986Google Scholar
  125. Jarrett RJ. Type 2 (non-insulin-dependent) diabetes mellitus and coronary heart disease: chicken, egg or neither? Diabetologia 26: 99–102, 1984PubMedGoogle Scholar
  126. Jarrett RJ, McCartney P, Keen H. The Bedford Survey: ten-year mortality rates in newly diagnosed diabetes, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia 22: 79–84, 1982PubMedGoogle Scholar
  127. Jarrett RJ, Shipley MJ. Mortality and associated risk factors in diabetes. Acta Endocrinologica 110 (Suppl. 272): 21–26, 1985Google Scholar
  128. Jarrett RJ, Stern MP. Non-insulin dependent diabetes. The 2nd Juvenile Diabetes Foundation International World Conference on Diabetes Research. New Frontiers, pp. 45–47, Juvenile Diabetic Foundation, 1988Google Scholar
  129. Jauch K-W, Hartl W, Guenther B, Wicklmayr M, Rett K, et al. Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus. European Journal of Clinical Investigation 17: 448–454, 1987PubMedGoogle Scholar
  130. Javier Z, Gershberg H, Hulse M. Ovulatory suppressants, estrogens and carbohydrate metabolism. Metabolism 17: 443–456, 1968PubMedGoogle Scholar
  131. Jeanrenaud X, Maeder E, Del Pozo E, Felber JP. Effect of an enkephalin-analogue (FK 33-824) on glucose tolerance in man. Acta Endocrinologica 104: 85–90, 1983PubMedGoogle Scholar
  132. Jones GR, Lazarus JH, Davies CJ, Greenwood RH. The effect of short term lithium carbonate in Type II diabetes mellitus. Hormone Metabolic Research 15: 422–424, 1983Google Scholar
  133. Joplin GF, Fraser R, Keeley KJ. Prednisone-glycosuria test for prediabetes. Lancet 2: 67–70, 1961PubMedGoogle Scholar
  134. Jung CY, Mookerjee BK. Inhibitory effect of frusemide on glucose transport. Journal of Laboratory Clinical Medicine 87: 960–966, 1976Google Scholar
  135. Kadowaki T, Miyake Y, Hagura R, Akanuma Y, Kajinuma H, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 26: 44–49, 1984PubMedGoogle Scholar
  136. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care 2: 120–126, 1979PubMedGoogle Scholar
  137. Kaplan JM, Mass JW, Pixley JM, Ross WD. Use of imipramine in diabetics. Journal of the American Medical Association 174: 511–517, 1960PubMedGoogle Scholar
  138. Keen H, Jarrett RJ, McCartney M. The ten-year follow-up of the Bedford Survey (1962–1972): glucose tolerance and diabetes. Diabetologia 22: 73–78, 1982PubMedGoogle Scholar
  139. Keeney EL. The condition of asthmatic patients after daily longterm corticosteroid treatment. Arizona Medicine 21: 463–469, 1964PubMedGoogle Scholar
  140. Kessler I. Mortality experience of diabetic patients. American Journal of Medicine 51: 715–724, 1971PubMedGoogle Scholar
  141. King H, Zimmet P, Raper LR, Balkau B. The natural history of impaired glucose tolerance in the micronesian population of Nauru: a six-year follow-up study. Diabetologia 26: 39–43, 1984PubMedGoogle Scholar
  142. Kizer JS, Vargas-Cordon M, Brendel K, Bressler R. The in-vitro inhibition of insulin secretion by diphenylhydantoin. Journal of Clinical Investigation 49: 1942–1948, 1970PubMedGoogle Scholar
  143. Kluft C, Preston FE, Malia RG, Bertina RM, Wijngaards G, et al. Stanozolol-induced changes in fibrinolysis and coagulation in healthy adults. Thrombosis and Haemostasis 51: 157–164, 1984PubMedGoogle Scholar
  144. Kolterman OG, Gray RS, Griffin J, Burstein P, Insel J, et al. Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus. Journal of Clinical Investigation 68: 957–969, 1981PubMedGoogle Scholar
  145. Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K. The effect of gemfibrozil on serum lipids in diabetic patients. Annals of Clinical Research 11: 240–245, 1979PubMedGoogle Scholar
  146. Korhonen T, Uusitupa M, Voutilainen E, Sarlund H, Laakso M, et al. Lack of effect of hepatic enzyme induction on metabolic control in patients with Type 2 (non-insulin-dependent) diabetes. Clinical Pharmacology and Therapeutics 41: 633–638, 1987PubMedGoogle Scholar
  147. Kotier MN, Berman L, Rubenstein AH. Hypoglycaemia precipitated by propranolol. Lancet 2: 1389–1390, 1966Google Scholar
  148. Krolewski AS, Czyzyk A, Janeczko D, Kopczynski J. Mortality from cardiovascular diseases among diabetics. Diabetologia 13: 345–350, 1977PubMedGoogle Scholar
  149. Lahtela JT, Gachalyi B, Eksymä S, Hämäläinen A, Sotainiemi EA. The effect of liver microsomal enzyme inducing and inhibiting drugs on insulin mediated glucose metabolism in man. British Journal of Clinical Pharmacology 21: 19–26, 1986PubMedGoogle Scholar
  150. Lahtela JT, Sarkka P, Sotaniemi EA. Phenobarbital treatment enhances insulin mediated glucose metabolism in man. Research Communications in Chemical Pathology and Pharmacology 44: 215–226, 1984PubMedGoogle Scholar
  151. Lancaster SG, Sorkin EM. Bisoprolol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. Drugs 36: 256–285, 1988PubMedGoogle Scholar
  152. Leary WP, Reyes AJ. Piretanide in the treatment of hypertension: effects on arterial blood pressure and several blood variables. South African Medical Journal 60: 925–928, 1981PubMedGoogle Scholar
  153. Leblanc H, Lachelin GCL, Abu-Fadil S, Yen SSC. The effect of dopamine infusions on insulin and glucagon secretion in man. Journal of Clinical Endocrinology and Metabolism 44: 196–198, 1977PubMedGoogle Scholar
  154. Lederle RM. Captopril and hydrochlorothiazide in the fixed combination multicenter trial. Journal of Cardiovascular Pharmacology 7 (Suppl. 1): 63–69, 1985Google Scholar
  155. Leslie RDG, Coats PM. Salbutamol-induced diabetic ketoacidosis. Correspondence. British Medical Journal 2: 768, 1977Google Scholar
  156. Levin SR, Booker J, Smith DF, Grodsky GM. Inhibition of insulin secretion in vitro by diphenylhydantoin. Journal of Clinical Endocrinology and Metabolism 3: 400–401, 1970Google Scholar
  157. Lewis PJ, Kohner EM, Petrie A, Dollery CT. Deterioration of glucose tolerance in hypertensive patients on prolonged diuretic treatment. Lancet 1: 564–566, 1976PubMedGoogle Scholar
  158. Lieberman P, Patterson R, Kunske R. Complications of long-term steroid therapy for asthma. Journal of Allergy and Clinical Immunology 49: 329–336, 1972PubMedGoogle Scholar
  159. Limone P, Cagliero E, Massara F, Molinatti GM. Reduced glucose tolerance after guanfacine in normal and obese patients. Hormone and Metabolic Research 15: 352, 1983PubMedGoogle Scholar
  160. Long CNH, Katzin B, Fry EG. The adrenal cortex and carbohydrate metabolism. Endocrinology 26: 309–344, 1940Google Scholar
  161. Lorenzi M, Tsalikian E, Bohannon NV, Gerich JE, Karam JH, et al. Differential effects of L-dopa and apomorphine secretion in man: evidence against central dopaminergic stimulation of glucagon. Journal of Clinical Endocrinology and Metabolism 45: 1154–1158, 1977PubMedGoogle Scholar
  162. Lundgren H, Björkman L, Keiding P, Lundmark S, Bengtsson C. Diabetes in patients with hypertension receiving pharmacological treatment. British Medical Journal 297: 1512, 1988PubMedGoogle Scholar
  163. Mannisto PT. Endocrine side effects of lithium. In Johnson FN (Ed.) Handbook of lithium therapy, pp. 310–322, MTP Press Ltd, Lancaster, 1980Google Scholar
  164. Marble A, Weir GC, Selenkow HA, Rose LI, Dluhy RC, et al. Endocrine diseases. In Speight TM (Ed.) Avery’s drug treatment: principles and practice of clinical pharmacology and therapeutics, 3rd ed., pp. 540–543, ADIS Press Ltd, Auckland, 1987Google Scholar
  165. Marks J, Howard AN. A comparative study of gemfibrozil and clofibrate in the treatment of hyperlipidaemia in patients with maturity-onset diabetes. Research and Clinical Forums 4: 95–103, 1982Google Scholar
  166. Marre M, Chatellier G, Leblanc H, Guyenne TT, Menard J, et al. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. British Medical Journal 297: 1092–1095, 1988PubMedGoogle Scholar
  167. Matthews DM, Wathen CG, Bell D, Collier A, Muir AL, et al. The effect of captopril on blood pressure and glucose tolerance in hypertensive non-insulin dependent diabetics. Postgraduate Medical Journal 62 (Suppl. 1): 73–75, 1986PubMedGoogle Scholar
  168. McMonagle J, Felig P. Effects of ethanol ingestion on glucose tolerance and insulin secretion in normal and diabetic subjects. Metabolism 24: 625–632, 1975PubMedGoogle Scholar
  169. McMurray J, Fraser DM. Captopril, enalapril and blood glucose. Correspondence. Lancet 1: 1035, 1986Google Scholar
  170. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal 291: 97–104, 1985Google Scholar
  171. Medical Research Council Working Party on Mild to Moderate Hypertension. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet 2: 539–542, 1981Google Scholar
  172. Metz SA, Halter JB, Robertson RP. Induction of defective insulin secretion and impaired glucose tolerance by clonidine. Diabetes 27: 554–562, 1978PubMedGoogle Scholar
  173. Micossi P, Pollavini G, Raggi U, Librents MC, Garimberti B, et al. Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus. Hormone and Metabolic Research 16: 59–63, 1984PubMedGoogle Scholar
  174. Mignano C, Berri F, Carta G, et al. Endorphins: a cause of noninsulin-dependent diabetes? In Belfiore F et al. (Eds) Diabetes mellitus: etiopathogenetic and metabolic aspects, pp. 212–214, Karger, Basel, 1984Google Scholar
  175. Miller RD. Atromid in the treatment of post-climacteric diabetes. Journal of Atherosclerotic Research 3: 694–700, 1963Google Scholar
  176. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. British Medical Journal 285: 685–688, 1982PubMedGoogle Scholar
  177. Monier H, Bravo EL, Tarazi RC. Glucose intolerance during chronic β-adrenergic blockade in man. Abstract. Clinical Pharmacology and Therapeutics 25: 237, 1979Google Scholar
  178. Moore MP, Elliott TW, Nicholls MG. Hormonal and metabolic effects of enalapril treatment in hypertensive subjects with NIDDM. Diabetes Care 11: 397–401, 1988PubMedGoogle Scholar
  179. Mueller-Oerlinghausen VB, Passoth PM, Poser W, Schleckt W. The influence of long-term treatment with major tranquillizers or lithium salts on the carbohydrate metabolism. Arzneimittel-Forschung/Drug Research 28: 1522–1524, 1978Google Scholar
  180. Muggeo M, Acipimox Co-operative Italian Group, University of Verona. Long-term multicentre trial with acipimox in diabetic patients with hyperlipoproteinaemia. Proceedings of the 6th International Meeting on Atherosclerosis and Cardiovascular Diseases, Bologna, October, 1986Google Scholar
  181. Multicentre Study Group. Multicentre comparison of amiloride, hydrochlorothiazide and hydrochlorothiazide plus amiloride in essential hypertension. Archives of Internal Medicine 141: 482–486, 1981Google Scholar
  182. Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT. Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up. Lancet 2: 1293–1295, 1982PubMedGoogle Scholar
  183. Neaton JD, Keller LH, Wentworth D, Borhani NO. Total and cardiovascular mortality in relation to cigarette smoking, serum cholesterol concentration and diastolic blood pressure among black and white males followed up for 5 years. American Heart Journal 108: 759–769, 1984PubMedGoogle Scholar
  184. Newman WP, Brodows RG. Aspirin causes tissue insensitivity to insulin in normal man. Journal of Clinical Endocrinology and Metabolism 57: 1102–1106, 1983PubMedGoogle Scholar
  185. Odigwe CO, McCulloch DO, Tunbridge WMG. A trial of the calcium antagonist nisoldipine in hypertensive non-insulin dependent diabetic patients. Diabetic Medicine 3: 463–467, 1986PubMedGoogle Scholar
  186. O’Hare JA. The enigma of insulin resistance and hypertension, insulin resistance, blood pressure and the circulation. American Journal of Medicine 84: 505–509, 1988PubMedGoogle Scholar
  187. Ohlson LO, Bjuro T, Larsson B, Eriksson H, Svardsudd K, et al. A cross-sectional analysis of glucose tolerance and cardiovascular disease in 67 year old men. Diabetic Medicine 6: 112–120, 1989PubMedGoogle Scholar
  188. Okada S, Miyi Y, Sato K, Masaki Y, Higuchi T, et al. Effect of clonidine on insulin secretion: a case report. Journal of International Medical Research 14: 299–302, 1986PubMedGoogle Scholar
  189. Olczak SA, Greenwood RH, Hales CN. Post-receptor insulin resistance after diazoxide in non-insulin dependent diabetics. Hormone Metabolic Research 18: 38–41, 1986Google Scholar
  190. Oli JM, Ikeakor IP. The use of piroxicam in diabetics with arthropathies. Current Therapeutic Research, Clinical Experiments 36: 46–50, 1984Google Scholar
  191. Osei K, Holland G, Falko JM. Indapamide: effects on apoprotein, lipoprotein and glucoregulation in ambulatory diabetic patients. Archives of Internal Medicine 146: 1973–1977, 1986PubMedGoogle Scholar
  192. Ostrander Jr LD, Francis Jr T, Hayner NS, Kjelsberg MO, Epstein FH. The relationship of cardiovascular disease to hyperglycaemia. Annals of Internal Medicine 62: 1188–1198, 1965PubMedGoogle Scholar
  193. Pagano G, Cavalco-Perin P, Cassader M, Bruno A, Ozzello A, et al. An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. Journal of Clinical Investigation 72: 1814–1820, 1983PubMedGoogle Scholar
  194. Palmieri M, Caffau S, Borgioni L, Chiozza R, Gotti G, et al. The influence of orally given verapamil as an antihypertensive agent on the glucose-induced insulin release in 10 mildly hypertensive patients with impaired glucose tolerance. International Symposium on Calcium Antagonism in Cardiovascular Therapy, Experience with Verapamil, Florence, October, 1980, pp. 141–143, Centro Editoriale Pubblicitario Italiano Roma, 1980Google Scholar
  195. Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. British Medical Journal 294: 1443–1447, 1987PubMedGoogle Scholar
  196. Parving HH, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. British Medical Journal. 297: 1086–1091, 1988PubMedGoogle Scholar
  197. Passariello N, Giugliano D, Quatraro A, Consoli G, Sgambato S, et al. Glucose tolerance and hormonal responses in heroin addicts: a possible role for endogenous opiates in the pathogenesis of non-insulin-dependent diabetes. Metabolism 32: 1163–1165, 1983PubMedGoogle Scholar
  198. Perley M, Kipnis DM. Effect of glucocorticoids on plasma insulin. New England Journal of Medicine 274: 1237–1241, 1966PubMedGoogle Scholar
  199. Perry-Keene DA, Larkins RG, Heyma P, Peter CT, Ross D, et al. The effect of long-term diphenylhydantoin therapy on glucose tolerance and insulin secretion: a controlled trial. Clinical Endocrinology 12: 575–580, 1980PubMedGoogle Scholar
  200. Peters BH, Samaan NA. Hyperglycaemia with relative hypoinsulinaemia in diphenylhydantoin toxicity. New England Journal of Medicine 281: 91–92, 1969PubMedGoogle Scholar
  201. Phillips G, Safrit H. Alcoholic diabetes: induction of glucose intolerance with alcohol. Journal of the American Medical Association 217: 1513–1519, 1971PubMedGoogle Scholar
  202. Podolsky S, Patavina CG. Hyperosmolar nonketotic diabetic coma: a complication of propranolol therapy. Metabolism 22: 685–693, 1973PubMedGoogle Scholar
  203. Polak JMM, Sullivan SN, Bloom SR, Facer P, Pearse AGE. En-kephalin-like immunoreactivity in the human gastrointestinal tract. Lancet 1: 972–974, 1977PubMedGoogle Scholar
  204. Politi A, Poggio G, Margiotta A. Can amiodarone induce hyperglycaemia and hypertriglyceridaemia? British Medical Journal 288: 285, 1984PubMedGoogle Scholar
  205. Raftos J, Bauer GE, Lewis RG. Clonidine in the treatment of severe hypertension. Medical Journal of Australia 1: 786–793, 1973PubMedGoogle Scholar
  206. Rapoport MI, Hurd HF. Thiazide-induced glucose intolerance treated with potassium. Archives of Internal Medicine 113: 405–408, 1964PubMedGoogle Scholar
  207. Rayfield EJ, George DT, Eichner HL, Hsu TH. L-Dopa stimulation of glucagon secretion in man. New England Journal of Medicine 293: 589–591, 1975PubMedGoogle Scholar
  208. Regal H, Lageder H, Irsigler K, Maggi E, Mandelli V, et al. Effect of a single oral dose of acipimox on glucose utilization after intravenous glucose load in obese patients. Drugs Under Experimental and Clinical Research 10: 621–625, 1984Google Scholar
  209. Reid J, MacDougall AI, Andrews MM. Aspirin and diabetes mellitus. British Medical Journal 4: 1071–1074, 1957Google Scholar
  210. Reid RL, Sandler JA, Yen SSC. Beta-endorphin stimulates the secretion of insulin and glucagon in diabetes mellitus. Metabolism 33: 197–199, 1984PubMedGoogle Scholar
  211. Reid RL, Yen SSC. Beta-endorphin stimulates the secretion of insulin and glucagon in humans. Journal of Clinical Endocrinology and Metabolism 52: 592–594, 1981PubMedGoogle Scholar
  212. Reilly IAG, FitzGerald GA. Aspirin in cardiovascular disease. Drugs 35: 154–176, 1988PubMedGoogle Scholar
  213. Rett K, Wicklmayr M, Dietze GJ. Hypoglycaemia in hypertensive diabetic patients treated with sulfonylureas, biguanides, and captopril. Correspondence. New England Journal of Medicine 319: 1609, 1988Google Scholar
  214. Reuter H. A variety of calcium channels. Nature 316: 391, 1985PubMedGoogle Scholar
  215. Rizza RA, Cryer PE, Haymond MW, Gerich JE. Adrenergic mechanism for the effects of epinephrine on glucose production and clearance in man. Journal of Clinical Investigation 65: 682–689, 1980PubMedGoogle Scholar
  216. Robinson D, Nilsson C, Leonard R, Horton E. Effects of loop diuretics on carbohydrate metabolism and electrolyte excretion. Journal of Clinical Pharmacology 21: 637–646, 1981PubMedGoogle Scholar
  217. Rojdmark S, Andersson DEH. Influence of verapamil on human glucose tolerance. American Journal of Cardiology 57 (Suppl. D): 39–43, 1986Google Scholar
  218. Röjdmark S, Andersson DEH, Hed R, Sunblad L. Calcium-antagonistic effects on glucose response to glucagon in patients with non-insulin-dependent diabetes mellitus and in normoglycaemic subjects. Hormone and Metabolic Research 13: 664–667, 1981PubMedGoogle Scholar
  219. Rosatti G, Maioli M, Aiello I, Farris A, Agnetti V. Effects of longterm L-dopa therapy on carbohydrate metabolism in patients with Parkinson’s disease. European Neurology 114: 229–239, 1976Google Scholar
  220. Royal College of General Practitioners Oral Contraceptive Study. Mortality among oral contraceptive users. Lancet 2: 727, 1979Google Scholar
  221. Salmela PI, Sotaniemi EA, Pelkowen RD. The evaluation of the drug-metabolizing capacity in patients with diabetes mellitus. Diabetes 29: 788–794, 1980PubMedGoogle Scholar
  222. Samaan NA, Dollery CT, Fraser R. Diabetogenic action of benzothiadiazines. Lancet 2: 1244–1246, 1963PubMedGoogle Scholar
  223. Samarthji LAL, Tolis G, Martin JB, Brown GM, Guyda H. Effect of clonidine on growth hormone, prolactin, luteinizing hormone, follicle-stimulating hormone and thyroid-stimulating hormone in the serum of normal men. Journal of Clinical Endocrinology and Metabolism 41: 827–832, 1975Google Scholar
  224. Sasaki A, Susuki T, Horiuchi N. Development of diabetes in Japanese subjects with impaired glucose tolerance: a seven year follow-up study. Diabetologia 22: 154–157, 1982PubMedGoogle Scholar
  225. Sasaki A, Uehara M, Horiuchi N, Hasagawa K. A long-term follow-up study of Japanese diabetic patients: mortality and causes of death. Diabetologia 25: 309–312, 1983PubMedGoogle Scholar
  226. Seviour PW, Teal TK, Richmond W, Elkeles RS. Serum lipids, lipoproteins and macrovascular disease in non-insulin-dependent diabetics: a possible new approach to prevention. Diabetic Medicine 5: 166–171, 1988PubMedGoogle Scholar
  227. Shah JH, De Leon-Jones FA, Shickler R, Nasr S, Mayer M, et al. Symptomatic reactive hypoglycaemia during glucose tolerance test in lithium-treated patients. Metabolism 35: 634–639, 1986PubMedGoogle Scholar
  228. Shamoon H, Baylor P, Kambosos D, Charlap S, Plawes S, et al. Influence of oral verapamil on glucoregulatory hormones in man. Journal of Clinical Endocrinology and Metabolism 60: 536–541, 1985PubMedGoogle Scholar
  229. Shanghai Diabetes Research Co-operative Group. Diabetes mellitus survey in Shanghai. Chinese Medical Journal 93: 663–672, 1980Google Scholar
  230. Shopsin B, Stern S, Gershon S. Altered carbohydrate metabolism during treatment with lithium carbonate. Archives of General Psychiatry 24: 566–571, 1972Google Scholar
  231. Sirtori CR, Bohme P, Azarnoff DL. Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. New England Journal of Medicine 287: 729–733, 1972PubMedGoogle Scholar
  232. Skarfors ET, Lithell HO, Selinus I, Åberg H. Do antihypertensive drugs precipitate diabetes in predisposed men? British Medical Journal 298: 1147–1152, 1989PubMedGoogle Scholar
  233. Small M, Forbes CD, MacCuish AC. Metabolic effects of stanozolol in Type II diabetes mellitus. Hormone and Metabolic Research 18: 647–648, 1986PubMedGoogle Scholar
  234. Smith GD, Amos TAS, Mahler R, Peters TJ. Effect of chloroquine on insulin and glucose homeostasis in normal subjects and patients with non-insulin dependent diabetes mellitus. British Medical Journal 294: 465–467, 1987PubMedGoogle Scholar
  235. Smith GD, Peters TJ. The localization in rat liver of alkaline phosphodiesterase to a discrete organelle implicated in ligand internalization. Biochimica et Biophysica Acta 716: 24–30, 1982PubMedGoogle Scholar
  236. Soreth JT, Dubb JW, Allison NL, Alexander F, Boden G, et al. Effect on the endocrine system of a new dopaminergic agent, ibopamine. Clinical Pharmacology and Therapeutics 41: 627–632,1987PubMedGoogle Scholar
  237. Sorkin EM, Heel RC. Guanfacine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 31: 301–336, 1986PubMedGoogle Scholar
  238. Sotaniemi EA, Arranto AJ, Salmela PI, Stengård JH, Pelkonen RO. Hepatic microsomal enzyme activity in patients with noninsulin dependent diabetes mellitus (NIDDM) and its clinical significance. Acta Endocrinologica 105 (Suppl. 262): 125–129, 1984Google Scholar
  239. Sotaniemi EA, Arranto AJ, Sutinen S, Stengård JH, Sutinen S. Treatment of non-insulin-dependent diabetes mellitus with enzyme inducers. Clinical Pharmacology and Therapeutics 33: 826–835, 1983PubMedGoogle Scholar
  240. Sotaniemi EA, Lahtela JT, Stengård J. Enzyme induction and glucose metabolism. In Sotaniemi EA & Pelkonen RO (Eds) pp. 219–230, Taylor and Francis, New York, 1987Google Scholar
  241. Spellacy WN. A review of carbohydrate metabolism and the oral contraceptives. American Journal of Obstetrics and Gynecology 104: 448–460, 1969PubMedGoogle Scholar
  242. Stahl-Bayliss CM, Kaiman CM, Laskin OL. Pentamidine-induced hypoglycaemia in patients with the acquired immune deficiency syndrome. Clinical Pharmacology and Therapeutics 39: 271–275, 1986PubMedGoogle Scholar
  243. Steinbach LH, Randall LO, Gustofson SR. 1,5-benzodiazepines. In Gordon M (Ed.) Psychopharmacological agents, Vol. 1, pp. 198–200, Academic Press, New York, 1964Google Scholar
  244. Stokes III J, Kannel WB, Wolf PA, Cupples LA, D’Agostino RB. The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. Circulation 75 (Suppl. V): 65–73, 1987Google Scholar
  245. Thomas DJ, Brown PM, Stubbs WA. Salbutamol induced diabetic ketoacidosis. British Medical Journal 2: 438, 1977PubMedGoogle Scholar
  246. Thomas JR. A review of 10 years of experience with indapamide as an antihypertensive agent. Hypertension 7 (Suppl. 11): 152–156, 1985Google Scholar
  247. Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. American Journal of Psychiatry 124: 978–982, 1968PubMedGoogle Scholar
  248. Töterrman K, Groop L, Groop PH, Kala R, Tolppanen EM, et al. Effect of beta-blocking drugs on beta-cell function and insulin sensitivity in hypertensive non-diabetic patients. European Journal of Clinical Pharmacology 26: 13–17, 1984Google Scholar
  249. Trost BN, Weidmann P. Effects of nitrendipine and other calcium antagonists on glucose metabolism in man. Journal of Cardiovascular Pharmacology 6 (Suppl. 7): 986–995, 1984Google Scholar
  250. Van der Velde CD, Gordon MW. Manic-depressive illness, diabetes mellitus, and lithium carbonate. Archives of General Psychiatry 21: 478–485, 1969PubMedGoogle Scholar
  251. Van Woert MH, Mueller PS. Glucose insulin and free fatty acid metabolism in Parkinson’s disease treated with levodopa. Clinical Pharmacology and Therapeutics 12: 360–367, 1971PubMedGoogle Scholar
  252. Vendsborg PB. Lithium treatment and glucose tolerance in melancholic patients. Acta Psychiatrica Scandinavica 59: 306–316, 1979PubMedGoogle Scholar
  253. Vendsborg PB, Prytz S. Glucose tolerance and serum lipids in man after long term lithium administration. Acta Psychiatrica Scandinavica 53: 64–69, 1976PubMedGoogle Scholar
  254. Vendsborg PB, Rafaelsen OJ. Lithium in man: effect on glucose tolerance and serum electrolytes. Acta Psychiatrica Scandinavica 49: 601–610, 1973PubMedGoogle Scholar
  255. Vester JW, Sunder JH, Aarons JH, Danowski TS. Long term monitoring during clofibrate therapy. Clinical Pharmacology and Therapeutics 11: 689–697, 1970PubMedGoogle Scholar
  256. Vierhapper H, Jorg J, Waldhausl W. Effect of acetyl-salicylic acid and of indomethacin or diuresis in man: the role of cyclooxygenase inhibition. Clinical Science 67: 579–583, 1984PubMedGoogle Scholar
  257. Waal-Manning HJ. Metabolic effects of β-adrenoreceptor blockers. Drugs 11 (Suppl. 1): 121–126, 1976PubMedGoogle Scholar
  258. Waitzkin L. A survey for unknown diabetics in a mental hospital. Diabetes 15: 97–104, 1966PubMedGoogle Scholar
  259. Walsh SP, Grant IWB. Corticosteroids in the treatment of chronic asthma. British Medical Journal 2: 796, 1966PubMedGoogle Scholar
  260. Weir GC. Non-insulin-dependent diabetes mellitus: interplay between β-cell inadequacy and insulin resistance. American Journal of Medicine 73: 461–464, 1982PubMedGoogle Scholar
  261. Whitcroft I. Do antihypertensive drugs precipitate diabetes? Correspondence. British Medical Journal 290: 322, 1985PubMedGoogle Scholar
  262. Whitcroft I, Wilkinson N, Rawthorne A, Thomas J, Davies JB. β-Adrenoceptor antagonists impair long-term glucose control in hypertensive diabetics: role of β-adrenoceptor selectivity and lipid solubility. Proceedings of the British Pharmacological Society, 9–11 April. British Journal of Clinical Pharmacology 22: 236P-237P, 1986Google Scholar
  263. WHO Expert Committee on Diabetes Mellitus. 2nd report. WHO Technical Report Series, No. 646, 1980Google Scholar
  264. WHO Study Group on Diabetes Mellitus. Diabetes mellitus. WHO Technical Report Series No. 727, 1985Google Scholar
  265. Wicklmayr M, Dietze G, Guenther B, Boettger I, Mayer L, et al. Improvement of glucose assimilation and protein degradation by bradykinin in maturity onset diabetics and in surgical patients. In Fujii S et al. Kinins 11, Vol. 76, pp. 569–576, Plenum, New York, 1979Google Scholar
  266. Wolff FW, Parmlcy WW, White K, Okun R. Further observations concerning the hyperglycaemic activity of benzothiadiazines. Diabetes 13: 115–121, 1964PubMedGoogle Scholar
  267. Woods KL, Wright AD, Kendall MJ, Black E. Lack of effect of propranolol and metoprolol on glucose tolerance in maturityonset diabetics. British Medical Journal 281: 1321, 1980PubMedGoogle Scholar
  268. Wray R, Sutcliffe SBJ. Propranolol-induced hypoglycaemia and myocardial infarction. Correspondence. British Medical Journal 2: 592, 1972Google Scholar
  269. Wright AD, Barber SQ, Kendall MJ, Poole PH. Beta-adrenoceptor-blocking drugs and blood sugar. British Medical Journal 1: 159–161, 1979PubMedGoogle Scholar
  270. Wynn V. Effect of duration of low-dose oral contraceptive administration on carbohydrate metabolism. American Journal of Obstetrics and Gynecology 142: 739–746, 1982PubMedGoogle Scholar
  271. Wynn V, Godsland I, Niththyanan Than R, Adams PW, Melrose J, et al. Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism. Lancet 1: 1045–1049, 1979PubMedGoogle Scholar
  272. Zavaroni I, Dall’Aglio E, Bonoka S, Alpi O, Passeu M, et al. Evidence that multiple risk factors for coronary artery disease exist in persons with abnormal glucose tolerance. American Journal of Medicine 83: 609–612, 1987PubMedGoogle Scholar
  273. Zimmett P. Epidemiology of diabetes and its macrovascular manifestations in Pacific populations: the medical effects of social progress. Diabetes Care 2: 144–153, 1979Google Scholar
  274. Zumoff B, Hellman L. Aggravation of diabetic hyperglycaemia by chlordiazepoxide. Journal of the American Medical Association 237: 1960–1961, 1977PubMedGoogle Scholar

Copyright information

© Adis International Limited 1990

Authors and Affiliations

  • Sharon O’Byrne
    • 1
  • John Feely
    • 1
  1. 1.Department of Pharmacology and Therapeutics, Trinity College Medical SchoolSt James’s HospitalDublin 8Ireland

Personalised recommendations